Rivaroxaban Versus Warfarin for Management of Obese African Americans With Non-Valvular Atrial Fibrillation or Venous Thromboembolism: A Retrospective Cohort Analysis

by Olivia S. Costa PharmD, Jan Beyer-Westendorf MD, Veronica Ashton MPH, Dejan Milentijevic PhD, MBA, Kenneth Todd Moore MS, Thomas J. Bunz PharmD, PhD, Craig I. Coleman PharmD
Published 2020-10-01

Rivaroxaban’s Impact on Renal Decline in Patients With Nonvalvular Atrial Fibrillation: A US MarketScan Claims Database Analysis

by Craig I. Coleman PharmD, Reinhold Kreutz MD, PhD, Nitesh Sood MD, Thomas J. Bunz PharmD, PhD, Anna-Katharina Meinecke PhD, Daniel Eriksson MSc, William L. Baker PharmD
Published 2019-08-01

Proportion of US Hospitalized Medically Ill Patients Who May Qualify for Extended Thromboprophylaxis

by Benjamin Miao PharmD, Bhavana Chalupadi PharmD, Brendan Clark PharmD, Alexis Descoteaux PharmD, Daniel Huang PharmD, Sabrina Ilham PharmD, Brian Ly PharmD, Alex C. Spyropoulos MD, Craig I. Coleman PharmD
Published 2019-05-01

Rivaroxaban Versus Low-Molecular-Weight Heparins in a Broad Cohort of Patients With Cancer-Associated Venous Thromboembolism: An Analysis of the OSCAR-US Program

by Kimberly Snow Caroti PharmD, Alok A. Khorana MD, Cecilia Becattini MD, Agnes Y.Y. Lee MD, Anders Ekbom MD, Marc Carrier MD, Alexander T. Cohen MD, Christopher Brescia BS, Khaled Abdelgawwad MSc, MBA, George Psaroudakis PhD, Marcela Rivera PhD, Bernhard Schaefer BS, Gunnar Brobert PhD, Craig I. Coleman PharmD
Published 2023-08-01